Editas Medicine, Inc. Segments Disclosure
| Year Ended December 31, | |||||||||||
| 2025 | 2024 | ||||||||||
| Collaboration and other research and development revenues | $ | 40,520 | $ | 32,314 | |||||||
| Operating expenses: | |||||||||||
| Employee related expenses | 33,076 | 61,136 | |||||||||
| External research and development expenses | 71,676 | 79,900 | |||||||||
| Facility expenses | 20,519 | 26,430 | |||||||||
| Stock-based compensation expenses | 2,968 | 8,642 | |||||||||
| Sublicense and license fees | 7,440 | 18,953 | |||||||||
Other expenses3 | 12,106 | 12,768 | |||||||||
| Employee related expenses | 13,041 | 24,335 | |||||||||
| Professional service expenses | 8,673 | 14,358 | |||||||||
| Intellectual property and patent related fees | 16,838 | 14,016 | |||||||||
| Stock-based compensation expenses | 7,032 | 12,775 | |||||||||
Facility and other expenses4 | 7,161 | 10,153 | |||||||||
| Interest expense related to sale of future revenues | (6,171) | (2,190) | |||||||||
| Other expense, net | (2,189) | (3) | |||||||||
| Interest income, net | 8,310 | 16,252 | |||||||||
| Net loss | $ | (160,060) | $ | (237,093) | |||||||
1 The years ended December 31, 2025 and 2024 include $57,832 and $8,582 of restructuring charges, respectively. | |||||||||||
2 The years ended December 31, 2025 and 2024 include $2,842 and $3,650 of restructuring charges, respectively | |||||||||||
3 Other expenses primarily consists of consultant fees and office expenses | |||||||||||
4 Facility and other expenses primarily consists of rent expense, insurance premiums, software licenses and office expenses | |||||||||||
Want the next Editas Medicine, Inc. segments disclosure the moment it drops?
Set a Sentinel and we'll alert you the moment Editas Medicine, Inc.'s next filing hits EDGAR. No credit card, your email never gets sold.
Historical Timeline
| Fiscal Year | Filed | |
|---|---|---|
| 2025 | Mar 9, 2026 | Showing above |
| 2024 | Mar 5, 2025 | |
About Segments Disclosures
Segment disclosures break a company into its reportable operating units, revealing revenue, profit, and asset allocation that consolidated financial statements obscure. Under ASC 280, segments must match how the chief operating decision maker views the business, providing a window into internal management structure and resource allocation priorities.
Key signals: compare segment margins to identify which units drive profitability and which destroy value. Watch for changes in the number of reportable segments — segment aggregation or disaggregation often coincides with strategic shifts or attempts to obscure declining performance. Intersegment elimination patterns reveal internal pricing practices. The reconciliation between segment totals and consolidated figures exposes corporate overhead allocation and unallocated items. Geographic revenue concentration highlights regulatory and currency exposure. Compare segment-level capital expenditure against segment revenue to assess where management is investing for future growth versus harvesting existing assets.